AstraZeneca and Merck attain FDA nod for a pancreatic cancer drug
Category: #health  By Saipriya Iyer  Date: 2019-12-31
  • share
  • Twitter
  • Facebook
  • LinkedIn

AstraZeneca and Merck attain FDA nod for a pancreatic cancer drug

The drug, dubbed Lynparza, is currently approved in almost 65 countries for the maintenance treatment of platinum-sensitive lapsed ovarian cancer.

British pharmaceutical firm AstraZeneca and Merck & Co. Inc. recently announced that its drug candidate olaparib, which is also known as Lynparza, has received approval from the U.S. Food and Drug Administration.

Reportedly, the drug is formulated to treat patients with pancreatic cancer that have mutations of genes which aids in suppressing tumors. Moreover, it is slated to double the life expectancy of pancreatic cancer patients.

As per reports, olaparib was cleared by the FDA to treat adults that have metastatic pancreatic cancer and whose health hasn’t deteriorated after 16 weeks of chemotherapy. The trial’s finding, which were published in The New England Journal of Medicine, suggested that the medicine minimized the risk of death or progression by 47%.

According to Dave Fredrickson, Executive VP of Oncology Business Unit, AstraZeneca, people previously suffering from advanced pancreatic cancer received poor outcomes because of the limited treatment advances over the past decade and aggressive nature of the disease. Lynparza comes as the only targeted drug in biomarker-selected patients going through advanced pancreatic cancer which is approved by the FDA.

Meanwhile, Roy Baynes, Chief Medical Officer & Senior Vice President, Merck Research Labs, revealed that the expanded approval of Lynparza comes as a substantial landmark for patients and reinforces the findings of germline BRCA testing in subjects with this disease.

Prior to the FDA approval, Merck & Co. Inc. and AstraZeneca had made headlines when Lynparza bagged approval from the Chinese regulators for treating a form of ovarian cancer. Sources close to the news claimed that the approval was based on Lynparza’s results from a late-stage trial in which it reduced the risk of death or disease progression by 70% when equated to placebo.
 

Source Credit: https://www.foxbusiness.com/lifestyle/astra-merck-get-fda-ok-for-pancreatic-cancer-drug



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Boehringer Ingelheim enrolls 1st patient in Phase 3 InPedILD™ trial
Boehringer Ingelheim enrolls 1st patient in Phase 3 InPedILD™ trial
By Saipriya Iyer

Boehringer Ingelheim, a pharmaceutical company, has recently announced the enrollment of 1st patient in its Phase 3 InPedILD™ trial. The trial will evaluate the dose and safety profile of nintedanib among childre...

Medtronic to turn Hyderabad into R&D hub with $160.3M investment
Medtronic to turn Hyderabad into R&D hub with $160.3M investment
By Saipriya Iyer

Medtronic, a medical device company, has reportedly announced an investment of Rs.1,200 crore ($160.3 million) to turn Hyderabad into its R&D center outside the U.S. The investment has been planned by the company s...

Toshiba exits PC business & transfers remaining 19.1% stake to Sharp
Toshiba exits PC business & transfers remaining 19.1% stake to Sharp
By Saipriya Iyer

Toshiba, a Japanese multinational conglomerate, has reportedly made an exit from the laptop business and transferred its remaining minority stake in the PC business to Sharp. This will mark the company’s terminat...